Roundup: Taiwan approves VUNO’s AI fundus instrument and extra briefs

Taiwan clears VUNO’s AI fundus evaluation instrument

South Korean agency VUNO has gained the approval of Taiwan’s Meals and Drug Administration to market its AI fundus evaluation software program.

VUNO Med-Fundus AI analyses pictures of the fundus to shortly detect places of lesions indicative of retinal ailments, together with diabetic retinopathy, macular illness and glaucoma.

This newest certification follows Taiwan FDA’s clearance for its different AI merchandise, VUNO-Med Chest X-ray and VUNO-Med Bone Age. Simply two months in the past, VUNO obtained Singapore’s clearance for VUNO Med-Fundus AI. 

---

Examine validates AIRS Medical’s AI resolution for denoising 3D MR pictures

AIRS Medical, a medical AI startup from South Korea, has not too long ago proved in a examine the aptitude of its AI-powered MRI reconstruction resolution, SwiftMR, to denoise and drastically enhance the standard of 3D MR pictures.

Based mostly on its findings, a deep neural network-based noise discount and picture high quality enchancment instrument outperformed the standard magnetisation-prepared speedy gradient-echo (MP-RAGE) sequence in bettering MR picture high quality. 

“We’re very happy that we’ve proved SwiftMR contributes to not solely lowering time but in addition [helping] make pictures nice, ultimately [helping] radiologists learn pictures with confidence,” mentioned AIRS Medical CEO Dr Hyeseong Lee.

---

Qure.ai packages options utilizing NVIDIA’s MONAI package

Indian well being expertise startup Qure.ai is without doubt one of the early adopters of NVIDIA’s newest open-source framework for deploying AI medical imaging purposes.

The MONAI Utility Packages (MAP) simplify the method of deploying an AI mannequin in an present healthcare ecosystem.

Qure.ai is now packaging its AI options for deployment utilizing MAPs, accelerating its scientific impression, in response to NVIDIA.

---

UK-based Cambridge Cognition brings mind well being options to China

London-listed Cambridge Cognition, a supplier of cognitive evaluation check options, has entered into a brand new partnership to convey its digital well being choices to China.

The corporate not too long ago signed a 10-year unique licensing deal and strategic partnership with Luca Healthcare, an area developer of digital well being evaluation instruments.

Luca will probably be making Cambridge Cognition’s CANTAB suite of digital mind well being exams obtainable in China by way of its LucaPlex platform. 

“China has over 265 million individuals aged 60 years and above, of which 40 million individuals have delicate cognitive impairment and 15 million individuals with a type of dementia. With neurodegenerative ailments, early analysis is the important thing to managing illness development. We are going to leverage Cambridge Cognition’s analysis, scientific know-how, and digital expertise to make obtainable superior cognitive evaluation instruments for the scientific trials market and the healthcare market in China,” mentioned Luca CEO Echo Chen.